SUN-101/eFlow®

October 17, 2016October 17, 2016

FDA Will Review New Drug Application for SUN-101/eFlow for COPD Treatment

News

The U.S. Food and Drug Administration (FDA) has accepted for review Sunovion’s new drug application (NDA) for its SUN-101/eFlow system as a long-term maintenance therapy for airflow obstruction in adults with chronic obstructive pulmonary ... Read more

August 4, 2016August 4, 2016

Sunovion Applies for FDA Approval of SUN-101 and eFlow as Long-term COPD Treatment

COPD

Sunovion Pharmaceuticals has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA), seeking approval of its SUN-101/eFlow technology as a long-term maintenance treatment of airflow obstruction in adult ... Read more

May 2, 2016October 17, 2016

Phase 3 Clinical Trials for COPD Treatment Return Positive Results, Sunovion Reports

COPD, News

Sunovion Pharmaceuticals, a biopharma focused on the development of medical solutions for respiratory, neurological, and psychiatric conditions, recently announced positive results from the Phase 3 trial program assessing SUN-101 (glycopyrrolate) for ... Read more